Search results
Results from the WOW.Com Content Network
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology , PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically.
The Progression Free Survival is usually used in analysing the results of the treatment for the advanced disease. The event for the progression free survival is that the disease gets worse or progresses, or the patient dies from any cause. Time to Progression is a similar endpoint that ignores patients who die before the disease progresses.
21935 Ensembl ENSG00000048462 ENSMUSG00000022496 UniProt Q02223 O88472 RefSeq (mRNA) NM_001192 NM_011608 RefSeq (protein) NP_001183 NP_035738 Location (UCSC) Chr 16: 11.97 – 11.97 Mb Chr 16: 11.13 – 11.14 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Serum B-cell maturation antigen (sBCMA) is the cleaved form of B-cell maturation antigen (BCMA), found at low levels in the serum ...
Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be classified as having “symptomatic deterioration”. Every effort should be made to document the objective progression even after discontinuation of treatment.
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
A pre-planned sub-group analyses showed that progression-free survival (PFS) was significantly longer for gefitinib than chemotherapy in patients with EGFR mutation positive tumours (HR 0.48, 95 per cent CI 0.36 to 0.64, p less than 0.0001), and significantly longer for chemotherapy than gefitinib in patients with EGFR mutation negative tumours ...
Progression-free survival, time without tumor progression in oncology Post-finasteride syndrome , a term associated with adverse effects that persist beyond the discontinuation of the medication finasteride
In statistics, median follow-up is the median time between a specified event and the time when data on outcomes are gathered. The concept is used in cancer survival analyses. [citation needed] Many cancer studies aim to assess the time between two events of interest, such as from treatment to remission, treatment to relapse, or diagnosis to death.